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Should Every
Drug-Eluting Stent
Be Deployed Directly?*Marco A. Magalhaes, MD, Sa’ar Minha, MD,
Augusto D. Pichard, MD
Washington, DC
Stents are the most remarkable advance to occur in coronary
artery disease management in the last 28 years. Stent re-
engineering transformed early hand-crimped, bulky systems
into safer, balloon-crimped devices, substantially reducing
strut thickness while maintaining radial strength. This made
direct stenting feasible and led interventional cardiologists
to pose the question, “Should every lesion undergo direct
stenting?” to which the answer was a resounding “Yes!”.if
eligible (1).See page 751Direct stenting (DS) is both safe and effective. A meta-
analysis of 24 randomized trials in the bare-metal stent
(BMS) era, including a total of 6,803 enrolled patients,
compared DS to stenting with pre-dilation and revealed
a reduction in myocardial infarction of 23% in favor of DS
(2). Both techniques enlarge the coronary lumen by similar
mechanisms, as judged by intravascular ultrasound (IVUS),
and both elicit an equivalent physiological response. How-
ever, there are distinct advantages to DS, including reduced
vessel wall trauma, reduced microvascular injury, and im-
proved myocardial perfusion grades in acute coronary syn-
dromes. Additionally, DS reduces radiation time and
procedural costs. On the other hand, primary failure can
occur in up to 17% of patients assigned to DS (3) as a result
of poor device performances, lack of operator expertise, and
inappropriate lesion selection. Accurate determination of
plaque and calcium distribution via IVUS decreases the
likelihood of unsuccessful DS attempts, which otherwise
may result in stent dislodgment and structural device
damage, and may also uncover potentially undilatable*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardiovascular
Interventions or the American College of Cardiology.
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in this editorial utilizes IVUS guidance in all procedures as
the ﬁrst step. This strategy allows for DS in most patients
except when IVUS suggests the presence of undilatable
lesions.
Drug-eluting stents (DES) have a more complex struc-
ture, with polymer and drug coatings that need to reach the
target lesion intact to yield an effective drug elution. Thus,
DS with DES is potentially susceptible to either unequal
expansion or polymer damage with consequent inhomoge-
neous pharmacokinetics that would reduce its maximal
beneﬁt. However, the safety and effectiveness of DS with
DES have been inferred primarily from observational (4,5)
and post-hoc (6–9) studies, as well as 1 underpowered
randomized trial (10). To date, no evidence for unequal
expansion has been uncovered, and there are conﬂicting
results on restenosis rates, with some studies showing a
reduction, which would favor DS (5,7,10), whereas others
document outcomes equivalent to stenting without pre-
dilation (6,9). Nevertheless, DS with DES has been in-
creasingly adopted as standard practice (11), although it is
technically “off-label,” and the available data are mostly
restricted to ﬁrst-generation DES.
Contemporary, second-generation DES are constructed
from a thin, highly ﬂexible metal alloy making them more
attractive for direct delivery. Also, mechanical damage to
second-generation DES architecture, such as longitudinal
deformation, has been occasionally reported (12,13). It is
plausible that the lack of pre-dilation in DS may contribute
to the need for post-dilation (12). Therefore, the question
posed at the start of this paper acquires a different per-
spective in the modern DES era, “Should every DES be
deployed directly?”
In this issue of JACC: Cardiovascular Interventions, Remkes
et al. (14) report on the STRESSED (direct Stenting To
Reduce REStenosis in Stent Era with Drug elution) trial,
the ﬁrst prospective, randomized study addressing the safety
and efﬁcacy of direct second-generation DES. The popula-
tion included patients undergoing elective percutaneous
coronary interventions for simple de novo lesions with
zotarolimus-eluting DES (Endeavor, Medtronic, Santa
Rosa, California) or everolimus-eluting DES (Promus,
Boston Scientiﬁc, Natick, Massachusetts) randomized to 3
strategies: 1) direct stenting; 2) stenting preceded by pre-
dilation; and 3) provisional stenting. The hypothesis assumed
that DS with DES was superior to pre-dilation or provisional
stenting. The primary endpoint was the minimal lumen
diameter at 9 months. Secondary outcomes included major
adverse cardiac events at 9 months and at 2 years follow-up.
Exploratory analyses were post-procedural troponin release
and binary restenosis.
The authors demonstrated no evidence of a difference
among DS, pre-dilation, or provisional stenting in regard
to minimal lumen diameter at 9 months (2.12  0.58 mm
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760vs. 2.17  0.67 mm vs. 1.99  0.69 mm, respectively;
p ¼ 0.556). Although the restenosis rate was higher in
provisional DES (3.4% vs. 6.7% vs. 11.5%; p ¼ 0.025), it
did not translate into differences in major adverse cardiac
events either at 9 months or at 2 years. Patients assigned to
DS had a lower frequency of troponin release than those
with conventional pre-dilation (11.2% vs. 24.8%; p ¼ 0.008)
or provisional stenting (11.2% vs. 21.9%; p ¼ 0.031).
One may ask what the relevance is when including a
provisional stent arm in the DES era? In fact, this consti-
tutes one of the unique aspects of the STRESSED study. In
the BMS era, a “stent-like” result in certain lesions following
balloon angioplasty had outcomes similar to BMS. The
superiority of systematic second-generation DES compared
with provisional stenting in reducing restenosis is remark-
able. This difference was obtained even with a high crossover
rate in which 77% of patients assigned to the provisional arm
received a DES. In other words, the remaining 23% of
patients skewed the late-loss distribution compared with DS
or pre-dilation (0.36  0.49 mm vs. 0.24  0.47 mm vs.
0.29  0.55 mm, respectively; p ¼ 0.05). Thus, systematic
second-generation DES implantation performs even better
than a more restrictive “stent-like” result following provi-
sional angioplasty.
Some caveats of the trial require further discussion.
First, the primary failure rate of DS at 18% is strikingly
high, considering the device proﬁle and the selection of
noncomplex lesions. This highlights the angiographic limi-
tations in accurately deﬁning DS eligibility. Second, neither
damage to the stent structure during DS failure attempts nor
rates of stent thrombosis have been reported. Third, the
sample chosen consists of patients with unusually simple
lesions, even compared with pivotal trials, and generalization
of these results to more complex scenarios may not be
advisable.
In summary, although DS with second-generation DES
did not yield better restenosis results than conventional
angioplasty, there were no harmful effects, and lower rates of
troponin elevation. Thus, DS remains an excellent technique
for most patients; however, in the absence of IVUS, oper-
ators should maintain a high level of awareness for poten-
tially undilatable lesions. In addition, a strategy of systematic
DES use reduces restenosis compared with provisional
stenting and should be the preferable approach. We com-
mend the investigators for providing evidence on one of
the most desirable stent features, successful direct delivery,
which is our real-life “bedside” test, showing that the
Endeavor and Promus platforms can safely undergo directdeployment. Whether this represents a DES class effect
cannot be determined, and should be the subject of addi-
tional studies.
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